Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Public ClinicalTrials.gov record NCT04958785. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study of Magrolimab Combination Therapy in Patients With Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of magrolimab in combination with nab-paclitaxel or paclitaxel (cohort 1) or with sacituzumab govitecan-hziy (cohort 2) in participants with non-surgically removable locally advanced or metastatic triple-negative breast cancer. The primary objective of this study for the safety run-in cohorts of the study is to evaluate the safety, tolerability, and recommended Phase 2 dose (RP2D) of magrolimab in combination with nab-paclitaxel or paclitaxel (Safety Run-In Cohort 1), and sacituzumab govitecan (Safety Run-In Cohort 2) in metastatic triple-negative breast cancer (mTNBC). This study in the Phase 2 Cohort 1 also compares the efficacy of magrolimab in combination with nab-paclitaxel or paclitaxel versus nab-paclitaxel or paclitaxel alone, as determined by progression-free survival (PFS) by investigator assessment. This study in the Phase 2 Cohort 2 also evaluates the efficacy of magrolimab in combination with sacituzumab govitecan as determined by confirmed objective response rate (ORR) by investigator assessment.
Study identification
- NCT ID
- NCT04958785
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 92 participants
Conditions and interventions
Conditions
Interventions
- Magrolimab Drug
- Nab-Paclitaxel Drug
- Paclitaxel Drug
- Sacituzumab Govitecan-hziy Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 14, 2021 (Actual)
- Primary completion
- Oct 8, 2024 (Actual)
- Completion
- Oct 8, 2024 (Actual)
- Last update posted
- Nov 4, 2025
2021 – 2024
United States locations
- U.S. sites
- 19
- U.S. states
- 11
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic | Phoenix | Arizona | 85054 | — |
| Women's Cancer Care | Fresno | California | 93710 | — |
| Providence Medical Foundation | Fullerton | California | 92835 | — |
| University of California San Francisco | San Francisco | California | 94115 | — |
| Saint John's Cancer Institute | Santa Monica | California | 90404 | — |
| Providence Medical Foundation | Santa Rosa | California | 95403 | — |
| Mayo Clinic | Jacksonville | Florida | 32224 | — |
| University Cancer & Blood Center,LLC | Athens | Georgia | 30607 | — |
| Winship Cancer Institute Emory University | Atlanta | Georgia | 30322 | — |
| Southeastern Regional Medical Center, LLC | Newnan | Georgia | 30265 | — |
| Orchard Healthcare Research Inc | Skokie | Illinois | 60077 | — |
| Ochsner Clinic Foundation | New Orleans | Louisiana | 70121 | — |
| Allina Health Cancer Institute | Minneapolis | Minnesota | 55407 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Astera Cancer Care | East Brunswick | New Jersey | 08816 | — |
| NYU Investigational Pharmacy, Laura & Isaac Perlmutter Cancer Center | New York | New York | 10016 | — |
| Stony Brook University | Stony Brook | New York | 11794 | — |
| Charleston Oncology | Charleston | South Carolina | 29414 | — |
| Huntsman Cancer Institute, University of Utah | Salt Lake City | Utah | 84112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04958785, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 4, 2025 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04958785 live on ClinicalTrials.gov.